(Q34466634)

2 August 2017

1 reference

title

Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker (English)

1 reference

2 August 2017

1 reference

Roehrborn CG

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

58

1 reference

2 August 2017

issue

6 Suppl 1

1 reference

2 August 2017

page(s)

55-63; discussion 63-4

1 reference

New words for old: lower urinary tract symptoms for "prostatism"

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Autonomic Receptors in Human Prostate Adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

alpha(1)-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Effects of alfuzosin on urethral and blood pressures in conscious male rats

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Alpha 1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901322-X

7 January 2021

10.1016/S0090-4295(01)01322-X

Identifiers

DOI

1 reference

2 August 2017

1 reference